Back to Browse Journals » Drug Design, Development and Therapy » Volume 5

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

Authors Channing J Paller, Emmanuel S Antonarakis

Published Date March 2011 Volume 2011:5 Pages 117—124


Published 10 March 2011

Channing J Paller, Emmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA

Abstract: Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new option for patients with CRPC whose disease progresses during or after docetaxel treatment. For most of these patients, cabazitaxel will now replace mitoxantrone (a drug that was FDA-approved because of its palliative effects) as the treatment of choice for docetaxel-refractory disease. The approval of cabazitaxel was based primarily on the TROPIC trial, a large (n = 755) randomized Phase III study showing an overall median survival benefit of 2.4 months for men with docetaxel-pretreated metastatic CRPC receiving cabazitaxel (with prednisone) compared to mitoxantrone (with prednisone). Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Preclinical and early clinical studies show that cabazitaxel retains activity in docetaxel-resistant tumors, and this was confirmed by the TROPIC study. Common adverse events with cabazitaxel include neutropenia (including febrile neutropenia) and diarrhea, while neuropathy was rarely observed. Thus, the combination of cabazitaxel and prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC, but this agent should be administered cautiously and with appropriate monitoring (especially in men at high risk of neutropenic complications).

Keywords: cabazitaxel, castration-resistant prostate cancer, clinical trial, docetaxel resistance, drug development

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:


Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:183-184

Published Date: 21 March 2011

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer

Golshayan AR, Antonarakis ES

Core Evidence 2013, 8:27-35

Published Date: 4 April 2013

Readers of this article also read:

Outcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study

Harald J Hamre, Claudia M Witt, Anja Glockmann, Renatus Ziegler, Gunver S Kienle et al

Drug Design, Development and Therapy 2008, 2:25-37

Published Date: 8 January 2008

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al

Drug Design, Development and Therapy 2008, 2:139-144

Published Date: 11 August 2008

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Sumanta Kumar Pal, Przemyslaw Twardowski, Oliver Sartor

Clinical Interventions in Aging 2010, 5:395-402

Published Date: 3 December 2010

Update on taxane development: new analogs and new formulations

Yared JA, Tkaczuk KH

Drug Design, Development and Therapy 2012, 6:371-384

Published Date: 11 December 2012

A review of tasquinimod in the treatment of advanced prostate cancer

Williamson SC, Hartley AE, Heer R

Drug Design, Development and Therapy 2013, 7:167-174

Published Date: 21 March 2013